{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:41:03Z","timestamp":1757702463733,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001"],"award-info":[{"award-number":["HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG060227"],"award-info":[{"award-number":["R21AG060227"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11606-022-07753-5","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T16:03:31Z","timestamp":1660061011000},"page":"3797-3804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7290-6838","authenticated-orcid":false,"given":"Dae Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Tatsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Jackson T.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle C.","family":"Odden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasan","family":"Beddhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon K.","family":"Bellows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E.","family":"Morisky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Tamariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Jen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"20","key":"7753_CR1","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"CE Lewis","year":"2021","unstructured":"Group SR, Lewis CE, Fine LJ, et al. Final Report of a Trial of Intensive Versus Standard Blood-Pressure Control. N Engl J Med. 2021;384(20):1921-1930. https:\/\/doi.org\/10.1056\/NEJMoa1901281","journal-title":"N Engl J Med."},{"issue":"4","key":"7753_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/M14-0295","volume":"161","author":"DA Zipkin","year":"2014","unstructured":"Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-Based Risk Communication: a Systematic Review. Ann Intern Med. 2014;161(4):270-280. https:\/\/doi.org\/10.7326\/M14-0295","journal-title":"Ann Intern Med."},{"issue":"1","key":"7753_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","volume":"21","author":"MA Hernan","year":"2010","unstructured":"Hernan MA. The Hazards of Hazard Ratios. Epidemiology. 2010;21(1):13-15. https:\/\/doi.org\/10.1097\/EDE.0b013e3181c1ea43","journal-title":"Epidemiology."},{"issue":"15","key":"7753_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","volume":"34","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. J Clin Oncol. 2016;34(15):1813-1819. https:\/\/doi.org\/10.1200\/JCO.2015.64.2488","journal-title":"J Clin Oncol."},{"issue":"19","key":"7753_CR5","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","volume":"30","author":"P Royston","year":"2011","unstructured":"Royston P, Parmar MK. The Use of Restricted Mean Survival Time to Estimate the Treatment Effect in Randomized Clinical Trials When the Proportional Hazards Assumption Is in Doubt. Stat Med. 2011;30(19):2409-2421. https:\/\/doi.org\/10.1002\/sim.4274","journal-title":"Stat Med."},{"key":"7753_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted Mean Survival Time: an Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials with a Time-to-Event Outcome. BMC Med Res Methodol. 2013;13:152. https:\/\/doi.org\/10.1186\/1471-2288-13-152","journal-title":"BMC Med Res Methodol."},{"issue":"22","key":"7753_CR7","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno H, Claggett B, Tian L, et al. Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. J Clin Oncol. 2014;32(22):2380-2385. https:\/\/doi.org\/10.1200\/JCO.2014.55.2208","journal-title":"J Clin Oncol."},{"issue":"2","key":"7753_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/M14-1741","volume":"163","author":"H Uno","year":"2015","unstructured":"Uno H, Wittes J, Fu H, et al. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015;163(2):127-134. https:\/\/doi.org\/10.7326\/M14-1741","journal-title":"Ann Intern Med."},{"issue":"2","key":"7753_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/biostatistics\/kxt050","volume":"15","author":"L Tian","year":"2014","unstructured":"Tian L, Zhao L, Wei LJ. Predicting the Restricted Mean Event Time with the Subject\u2019s Baseline Covariates in Survival Analysis. Biostatistics. 2014;15(2):222-233. https:\/\/doi.org\/10.1093\/biostatistics\/kxt050","journal-title":"Biostatistics."},{"key":"7753_CR10","doi-asserted-by":"publisher","unstructured":"Kloecker DE, Davies MJ, Khunti K, Zaccardi F. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M19-3286","DOI":"10.7326\/M19-3286"},{"issue":"22","key":"7753_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimaraes","year":"2020","unstructured":"Guimaraes HP, Lopes RD, de Barros ESPGM, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020;383(22):2117-2126. https:\/\/doi.org\/10.1056\/NEJMoa2029603","journal-title":"N Engl J Med."},{"issue":"10","key":"7753_CR12","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1111\/jgs.15509","volume":"66","author":"AR Orkaby","year":"2018","unstructured":"Orkaby AR, Rich MW, Sun R, Lux E, Wei LJ, Kim DH. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. J Am Geriatr Soc. 2018;66(10):1987-1991. https:\/\/doi.org\/10.1111\/jgs.15509","journal-title":"J Am Geriatr Soc."},{"issue":"11","key":"7753_CR13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","volume":"2","author":"DH Kim","year":"2017","unstructured":"Kim DH, Uno H, Wei LJ. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. JAMA Cardiol. 2017;2(11):1179-1180. https:\/\/doi.org\/10.1001\/jamacardio.2017.2922","journal-title":"JAMA Cardiol."},{"issue":"1","key":"7753_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2018.07.026","volume":"132","author":"ZR McCaw","year":"2019","unstructured":"McCaw ZR, Orkaby AR, Wei LJ, Kim DH, Rich MW. Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted Mean Survival Time. Am J Med. 2019;132(1):13-15. https:\/\/doi.org\/10.1016\/j.amjmed.2018.07.026","journal-title":"Am J Med."},{"issue":"12","key":"7753_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jchf.2020.07.005","volume":"8","author":"C Perego","year":"2020","unstructured":"Perego C, Sbolli M, Specchia C, et al. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. JACC Heart Fail. 2020;8(12):973-983. https:\/\/doi.org\/10.1016\/j.jchf.2020.07.005","journal-title":"JACC Heart Fail."},{"issue":"12","key":"7753_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jchf.2020.09.003","volume":"8","author":"ES Leifer","year":"2020","unstructured":"Leifer ES, Mentz RJ. Patient-Centered Measures of Treatment Benefit. JACC Heart Fail. 2020;8(12):996-998. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.003","journal-title":"JACC Heart Fail."},{"key":"7753_CR17","doi-asserted-by":"publisher","unstructured":"Kim DH, Shi SM, Carroll D, Najafzadeh M, Wei LJ. Restricted Mean Survival Time Versus Conventional Measures for Treatment Decision-making. J Am Geriatr Soc. 2021. https:\/\/doi.org\/10.1111\/jgs.17195","DOI":"10.1111\/jgs.17195"},{"key":"7753_CR18","doi-asserted-by":"publisher","unstructured":"Krishnaswami A, Peterson ED, Kim DH, Goyal P, Rich MW. Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time-Insights from the SPRINT Trial. Am J Med. 2020. https:\/\/doi.org\/10.1016\/j.amjmed.2019.12.050","DOI":"10.1016\/j.amjmed.2019.12.050"},{"issue":"17","key":"7753_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/eurheartj\/ehy770","volume":"40","author":"MJ Stensrud","year":"2019","unstructured":"Stensrud MJ, Aalen JM, Aalen OO, Valberg M. Limitations of Hazard Ratios in Clinical Trials. Eur Heart J. 2019;40(17):1378-1383. https:\/\/doi.org\/10.1093\/eurheartj\/ehy770","journal-title":"Eur Heart J."},{"issue":"5","key":"7753_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1740774514537404","volume":"11","author":"WT Ambrosius","year":"2014","unstructured":"Ambrosius WT, Sink KM, Foy CG, et al. The Design and Rationale of a Multicenter Clinical Trial Comparing Two Strategies for Control of Systolic Blood Pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532-546. https:\/\/doi.org\/10.1177\/1740774514537404","journal-title":"Clin Trials."},{"key":"7753_CR21","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SPRINT Research Group","year":"2015","unstructured":"SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-2116. https:\/\/doi.org\/10.1056\/NEJMoa1511939","journal-title":"N Engl J Med."},{"key":"7753_CR22","doi-asserted-by":"publisher","unstructured":"Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >\/=75 Years: A Randomized Clinical Trial. JAMA. 2016. https:\/\/doi.org\/10.1001\/jama.2016.7050","DOI":"10.1001\/jama.2016.7050"},{"issue":"6","key":"7753_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med."},{"issue":"3","key":"7753_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00004479-200407000-00011","volume":"27","author":"AJ Selim","year":"2004","unstructured":"Selim AJ, Fincke G, Ren XS, et al. Comorbidity Assessments Based on Patient Report: Results from the Veterans Health Study. J Ambul Care Manage. 2004;27(3):281-295. https:\/\/doi.org\/10.1097\/00004479-200407000-00011","journal-title":"J Ambul Care Manage."},{"key":"7753_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.dadm.2018.09.003","volume":"10","author":"SA Milani","year":"2018","unstructured":"Milani SA, Marsiske M, Cottler LB, Chen X, Striley CW. Optimal Cutoffs for the Montreal Cognitive Assessment Vary by Race and Ethnicity. Alzheimers Dement (Amst). 2018;10:773-781. https:\/\/doi.org\/10.1016\/j.dadm.2018.09.003","journal-title":"Alzheimers Dement (Amst)."},{"issue":"5","key":"7753_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/gerona\/glv228","volume":"71","author":"NM Pajewski","year":"2016","unstructured":"Pajewski NM, Williamson JD, Applegate WB, et al. Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial. J Gerontol A Biol Sci Med Sci. 2016;71(5):649-655. https:\/\/doi.org\/10.1093\/gerona\/glv228","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"3","key":"7753_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1053\/j.ajkd.2017.08.021","volume":"71","author":"MV Rocco","year":"2018","unstructured":"Rocco MV, Sink KM, Lovato LC, et al. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2018;71(3):352-361. https:\/\/doi.org\/10.1053\/j.ajkd.2017.08.021","journal-title":"Am J Kidney Dis."},{"issue":"19","key":"7753_CR28","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006","journal-title":"J Am Coll Cardiol."},{"key":"7753_CR29","doi-asserted-by":"publisher","unstructured":"Guiding Principles for the Care of Older Adults with Multimorbidity: an Approach for Clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60(10):E1-E25. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.04188.x","DOI":"10.1111\/j.1532-5415.2012.04188.x"},{"issue":"5","key":"7753_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamacardio.2019.6192","volume":"5","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Juraschek SP, Solomon SD. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol. 2020;5(5):576-581. https:\/\/doi.org\/10.1001\/jamacardio.2019.6192","journal-title":"JAMA Cardiol."},{"issue":"19","key":"7753_CR31","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2020.4249","volume":"323","author":"D Hughes","year":"2020","unstructured":"Hughes D, Judge C, Murphy R, et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: a Systematic Review and Meta-analysis. JAMA. 2020;323(19):1934-1944. https:\/\/doi.org\/10.1001\/jama.2020.4249","journal-title":"JAMA."},{"issue":"3","key":"7753_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/jgs.16272","volume":"68","author":"NM Pajewski","year":"2020","unstructured":"Pajewski NM, Berlowitz DR, Bress AP, et al. Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: a Secondary Analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc. 2020;68(3):496-504. https:\/\/doi.org\/10.1111\/jgs.16272","journal-title":"J Am Geriatr Soc."},{"issue":"9","key":"7753_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050335","volume":"11","author":"S Shi","year":"2021","unstructured":"Shi S, Gouskova N, Najafzadeh M, Wei LJ, Kim DH. Intensive Versus Standard Blood Pressure Control in Type 2 Diabetes: a Restricted Mean Survival Time Analysis of a Randomised Controlled Trial. BMJ Open. 2021;11(9):e050335. https:\/\/doi.org\/10.1136\/bmjopen-2021-050335","journal-title":"BMJ Open."},{"issue":"6","key":"7753_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/ajh\/hpaa010","volume":"33","author":"A Botchway","year":"2020","unstructured":"Botchway A, Buhnerkempe MG, Prakash V, Al-Akchar M, Adekola B, Flack JM. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: a Post Hoc Analysis of the SPRINT Trial. Am J Hypertens. 2020;33(6):528-533. https:\/\/doi.org\/10.1093\/ajh\/hpaa010","journal-title":"Am J Hypertens."},{"key":"7753_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-015-0328-1","volume":"13","author":"J Warwick","year":"2015","unstructured":"Warwick J, Falaschetti E, Rockwood K, et al. No Evidence that Frailty Modifies the Positive Impact of Antihypertensive Treatment in Very Elderly People: an Investigation of the Impact of Frailty Upon Treatment Effect in the HYpertension in the Very Elderly Trial (HYVET) Study, a Double-Blind, Placebo-Controlled Study of Antihypertensives in People with Hypertension Aged 80 and Over. BMC Med. 2015;13:78. https:\/\/doi.org\/10.1186\/s12916-015-0328-1","journal-title":"BMC Med."},{"issue":"18","key":"7753_CR36","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1001\/jama.2016.14909","volume":"316","author":"DH Kim","year":"2016","unstructured":"Kim DH. Intensive vs Standard Blood Pressure Control for Older Adults. JAMA. 2016;316(18):1921. https:\/\/doi.org\/10.1001\/jama.2016.14909","journal-title":"JAMA."},{"key":"7753_CR37","doi-asserted-by":"publisher","unstructured":"Tian L, Jin H, Uno H, et al. On the Empirical Choice of the Time Window for Restricted Mean Survival Time. Biometrics. 2020. https:\/\/doi.org\/10.1111\/biom.13237","DOI":"10.1111\/biom.13237"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-022-07753-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:01:53Z","timestamp":1691539313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-022-07753-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":37,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7753"],"URL":"https:\/\/doi.org\/10.1007\/s11606-022-07753-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"type":"print","value":"0884-8734"},{"type":"electronic","value":"1525-1497"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"26 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}